Search results

Skip to results

Type

Status

Last updated

Showing 1 to 4 of 4 results for siponimod

  1. Siponimod for treating secondary progressive multiple sclerosis (TA656)

    Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.

  2. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

  3. Cladribine for treating relapsing multiple sclerosis [ID6263]

    In development [GID-TA11293] Expected publication date: 23 April 2025

  4. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.